C114P: Burosumab Biosimilar, Human FGF23 Monoclonal Antibody
Recombinant Humanized IgG1 kappa Monoclonal Antibody.
Specificity/Sensitivity: The in vivo grade burosumab biosimilar specifically binds to the FGF23 protein.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by burosumab.BP000186-CYT-020: Recombinant Human FGF 23
Source: E. coli-derived.
The biological activity was measured in a cell proliferation assay using NIH/3T3 mouse embryonic fibroblasts. The ED50 for this effect is typically 0.05-0.5 ug/ml in the presence of 5 ug/ml of Recombinant Mouse Klotho and 10 ug/ml of heparin.
Purity > 95%, by SDS-PAGE.BP000186-CYT-028: Recombinant Human FGF 23 C-Terminal
Source: E. coli-derived.
Purity: > 90.0% as determined by densitometric image analysis.
Applications: WB.BP000186-CYT-374: Recombinant Human FGF 23, His Tag
Source: E. coli-derived.
Treatment with hrFGF23 has been shown to induce FGFR mediated Erk phosphorylation, reduce plasma PTH levels in rats and to reduce blood phosphate levels (Ref 1).
Purity > 90%, by SDS-PAGE and RP-HPLC.